EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Gene editing: Towards the third generation of adoptive T-cell transfer therapies

Cristina Puig-Saus, Antoni Ribas

Immuno-Oncology Technology · 2019

DOI: 10.1016/j.iotech.2019.06.001 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immuno-Oncology Technology, 2019. Verfasst von Cristina Puig-Saus und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, …. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Parker Institute for Cancer Immunotherapy, National Institutes of Health, Ressler Family Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

First-generation adoptive T-cell transfer (ACT) administering tumor-infiltrating lymphocytes (TILs), and second-generation ACT using autologous T cells genetically modified to express tumor-specific T-cell receptors (TCRs) or chimeric antigen receptors (CARs) have both shown promise for the treatment of several cancers, including melanoma, leukemia and lymphoma. However, these treatments require labor-intensive manufacturing of the cell product for each patient, frequently utilize lentiviral or retroviral vectors to genetically modify the T cells, and have limited antitumor efficacy in solid tumors. Gene editing is revolutionizing the field of gene therapy, and ACT is at the forefront of this revolution. Gene-editing technologies can be used to re-engineer the phenotype of T cells to increase their antitumor potency, to generate off-the-shelf ACT products, and to replace endogenous TCRs with tumor-specific TCRs or CARs using homology-directed repair (HDR) donor templates. Adeno-associated viral vectors or linear DNA have been used as HDR donor templates. Of note, non-viral delivery substantially reduces the time required to generate clinical-grade reagents for manufacture of T-cell products-a critical step for the translation of personalized T-cell therapies. These technological advances in the field using gene editing open the door to the third generation of ACT therapies.

Schlagwörter

Stichwörter der Autor:innen

Adoptive T-cell therapyGene editing in T cellsNon-viral gene editing in T cells

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, USA.
  • Division of Surgical Oncology, Department of Surgery, UCLA, Los Angeles, USA.
  • Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, USA.
  • Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, USA.

Förderung

  • Parker Institute for Cancer Immunotherapy
  • National Institutes of Health
  • Ressler Family Fund

Zitieren

APA

Puig-Saus, C., & Ribas, A. (2019). Gene editing: Towards the third generation of adoptive T-cell transfer therapies. Immuno-Oncology Technology. https://doi.org/10.1016/j.iotech.2019.06.001

Vancouver

Puig-Saus C, Ribas A. Gene editing: Towards the third generation of adoptive T-cell transfer therapies. Immuno-Oncology Technology. 2019. doi:10.1016/j.iotech.2019.06.001

BibTeX
@article{PuigSaus2019,
  author = {Puig-Saus, Cristina and Ribas, Antoni},
  title = {Gene editing: Towards the third generation of adoptive T-cell transfer therapies},
  journal = {Immuno-Oncology Technology},
  year = {2019},
  doi = {10.1016/j.iotech.2019.06.001}
}
Kostenlos starten →